PharmaBoardoom media partner of biggest ever CPhI Worldwide
CPhI Worldwide 2014, held this year in Paris, was the largest ever event held by the organizers, with more than 36,000 attendees and 2,500 exhibitors. PharmaBoardroom was a media partner…
Alfa Wassermann is a pharmaceutical group with an Italian heart and an international outlook. For over sixty years, it has researched, manufactured and distributed drugs of primary importance for human health, allowing people to benefit from new discoveries in medicine, biology and genomics. Today the Group operates in 12 different countries and employs approximately 1,370 employees, 670 of which in Italy.
Alfa Wassermann´s strategy is to focus on the gastro-intestinal area. Already present in IBS, constipation and diarrhoea, with the launch of Rifaximin-alpha 500 they will be active in a further major gastro-intestinal related area, namely hepatic encephalopathy. In France market authorization was received for Rifaximin-alpha 500mg in January 2015. Alfa Wassermann and its partner Norgine will jointly promote and manage the clinical development of Rifaximine alpha 550 mg in France.
Contact
ALFA WASSERMANN PHARMA SAS
67, rue Anatole France
92300 Levallois Perret – France
Ph. +33 1 41 27 25 10 – Fax +33 1 47 58 77 04
CPhI Worldwide 2014, held this year in Paris, was the largest ever event held by the organizers, with more than 36,000 attendees and 2,500 exhibitors. PharmaBoardroom was a media partner…
Nycomed lost an important patent with Pantoprazole in the middle of 2009, which has undoubtedly warranted some restructuring. What has been the impact of this loss on business in France,…
BMS recently announced divesting from their facilities in Epernon and Meymac but at the same time reinforcing manufacturing in Agen. Could you speak to strategy of this restructuring within France…
You worked for many years in emerging markets, especially in Latin America, but also in neighbor countries such as Spain. How these previous experiences in very different markets can now…
In the wake of the most recent CSIS meeting, LFB and Sanofi-Aventis announced the intention to collaborate in bioproduction. What are the terms to this agreement and what are the…
We have had the chance to interview a number of Teva’s subsidiaries in Europe, and witnessed how each of them has dealt with the strong transformations that the group has…
Historically, UCB Pharma had a much more ‘traditional’ approach to the industry with a broader scope of operations. Recently, the company reoriented in the direction of biopharmaceuticals by moving away…
Novo Nordisk just celebrated 50 years in France; what have been some of the more recent events that have marked the affiliate’s time here? If you look from the perspective…
Baxter is approaching 40 years in France, what have been the major milestones of the group during this period and what is the importance of France to the group? During…
Sandoz has set important trends in the pharmaceutical market, first by creating a leading global generics business under the umbrella of parent company Novartis, and secondly by investing heavily in…
How would you define the Institut Pasteur’s relationship with the pharmaceutical industry and how it has evolved in recent years? Since its foundation 120 years ago, the Institut Pasteur has…
Nordic Pharma has been established in the French market since 2002 as one of its first steps towards internationalization. What have been the main milestones and achievements of Nordic in…
See our Cookie Privacy Policy Here
